Combo Trials Aim to Clarify Optimal Radium-223 Use in mCRPC
August 16th 2016Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC
August 11th 2016Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer
August 11th 2016Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.
Expert Stresses Importance of PSA-Based Screening in Early-Stage Prostate Cancer
July 21st 2016Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.
Stadler Shares Treatment Updates, Questions in Castration-Sensitive Prostate Cancer
July 12th 2016Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.
Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer
May 19th 2016Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.
Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer
March 28th 2016Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.
Checkpoint Inhibitors Show Promise in Triple-Negative Breast Cancer
Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.
Dr. Villaflor on RAVD of Radiotherapy With Induction Chemotherapy in HNSCC
July 21st 2015Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.
Dr. Nanda on Immunotherapy in Metastatic TNBC
July 18th 2015Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.
Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO
June 25th 2015OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.
Obama Signs SGR Repeal, Heralding New Era in Medicare Reimbursement
With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.
Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma
March 25th 2015OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.